Actively Recruiting

Phase Not Applicable
Age: 18Years - 40Years
All Genders
NCT07561580

Botulinum Toxin Type A for Frontal Hyperhidrosis

Led by Tishreen University · Updated on 2026-05-01

30

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Frontal hyperhidrosis is a form of primary focal hyperhidrosis that significantly impairs patients' quality of life due to excessive visible sweating in the forehead region. Conventional treatment options often show limited efficacy or may be associated with undesirable side effects. This study aims to evaluate the efficacy and safety of intradermal injections of Botulinum Toxin Type A in patients with primary frontal hyperhidrosis. Clinical outcomes will be assessed using Minor's iodine-starch test, the Hyperhidrosis Disease Severity Scale (HDSS), and patient satisfaction scores. Participants will be followed up one month after treatment to evaluate therapeutic response and potential adverse effects.

CONDITIONS

Official Title

Botulinum Toxin Type A for Frontal Hyperhidrosis

Who Can Participate

Age: 18Years - 40Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged between 18 and 40 years
  • Diagnosed with primary focal frontal hyperhidrosis confirmed by sweat production over 50 mg/min and HDSS score of 3 or higher
  • Moderate to severe hyperhidrosis as defined by HDSS
  • Inadequate response to topical antiperspirant therapy
  • No Botulinum toxin type A treatment in the last 6 months
  • No other hyperhidrosis treatments used in the last 3 months
Not Eligible

You will not qualify if you...

  • Secondary hyperhidrosis caused by systemic diseases like hyperthyroidism, diabetes, or neurological conditions
  • Neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome
  • Active skin conditions or anatomical issues in the forehead area, including infections, inflammation, or scars
  • Known allergy to Botulinum toxin or its ingredients
  • Pregnancy or breastfeeding
  • Use of medications that interfere with Botulinum toxin activity, such as aminoglycosides, within one month before treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Latakia University Hospital

Latakia, Syria

Actively Recruiting

Loading map...

Research Team

Z

Zeinab Y Mohammad, MD

CONTACT

M

Mohamad A Ismaiel, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here